Stroke RSS Page 2

Filtered By:
Specialty: Hematology
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Vitamin K Antagonists: Beyond Bleeding
Abstract Warfarin is the most widely used oral anticoagulant in clinical use today. Indications range from prosthetic valve replacement to recurrent thromboembolic events due to antiphospholipid syndrome. In hemodialysis (HD) patients, warfarin use is even more frequent than in the nonrenal population due to increased cardiovascular comorbidities. The use of warfarin in dialysis patients with atrial fibrillation requires particular caution because side effects may outweigh the assumed benefit of reduced stroke rates. Besides increased bleeding risk, coumarins exert side effects which are not in the focus of clinical routin...
Source: Seminars In Dialysis - January 9, 2014 Category: Hematology Authors: Thilo Krüger, Jürgen Floege Tags: Review Source Type: research

Practical Approach to Evaluate Asymptomatic Coronary Artery Disease in End‐Stage Renal Disease Patients at the Initiation of Dialysis
Abstract The high prevalence of significant asymptomatic coronary artery disease (CAD) has been reported in patients with end‐stage renal disease (ESRD) at the initiation of dialysis. However, the approach to evaluate asymptomatic CAD for these patients has not been established. The aim of this study is to assess the applicability of our practical approach at the initiation of dialysis. We prospectively enrolled 182 consecutive ESRD patients who initiated dialysis. After echocardiography as primary screening, pharmacologic stress thallium‐201 scintigraphy and/or coronary angiography (CAG) were performed to diagnose CAD...
Source: Therapeutic Apheresis and Dialysis - April 10, 2014 Category: Hematology Authors: Akihito Tanaka, Masaki Sakakibara, Hiroaki Asada, Toshikazu Tanaka, Hideki Ishii, Toyoaki Murohara Tags: Original Article Source Type: research

Cerebral Blood Flow in Patients With Peritoneal Dialysis by an Easy Z‐Score Imaging System for Brain Perfusion Single‐Photon Emission Tomography
In conclusion, all PD patients in the present study had decreased rCBF irrespective of MMSE scores.
Source: Therapeutic Apheresis and Dialysis - June 26, 2014 Category: Hematology Authors: Rei Isshiki, Shuzo Kobayashi, Masao Iwagami, Daimu Tsutumi, Yasuhiro Mochida, Kunihiro Ishioka, Machiko Oka, Kyoko Maesato, Hidekazu Moriya, Takayasu Ohtake, Sumi Hidaka Tags: Original Article Source Type: research

Erythropoiesis-stimulating agents and thrombotic events in dialysis patients
Erythropoiesis-stimulating agents (ESA) have been associated with a higher cardiovascular event and mortality rate in dialysis patients. The ESA-associated risk of arterial thrombotic events is mainly based on composite endpoints of anemia-correction trials targeting high hemoglobin levels. The ESA-associated risk of venous thromboembolism (VTE) has not been studied in dialysis patients yet. We therefore aimed to determine the association between ESA use and dose with ischemic stroke, myocardial infarction (MI) and VTE.
Source: Thrombosis Research - August 1, 2014 Category: Hematology Authors: Marit M. Suttorp, Tiny Hoekstra, Gürbey Ocak, Anouk T.N. van Diepen, Ilka Ott, Moshe Mittelman, Ton J. Rabelink, Raymond T. Krediet, Friedo W. Dekker Source Type: research

Piperacillin/tazobactam‐induced neurotoxicity in a hemodialysis patient: A case report
This report presents a case of a hypertensive and diabetic 67‐year‐old woman in regular hemodialysis, which previously had a stroke. She was hospitalized presenting pneumonia, which was initially treated with cefepime. Two days after treatment, she presented dysarthria, left hemiparesis, ataxia, and IX and X cranial nerves paresis. Computed tomography showed no acute lesions and cefepime neurotoxicity was hypothesized, and the antibiotic was replaced by piperacillin/tazobactam. The neurologic signs disappeared; however, 4 days after with piperacillin/tazobactam treatment, the neurological manifestations returned. A new...
Source: Hemodialysis International - July 1, 2014 Category: Hematology Authors: Precil Diego M. M. Neves, Fernanda M. Freitas, Christiane A. Kojima, Beatriz L. Carmello, Rodrigo Bazan, Pasqual Barretti, Luis C. Martin Tags: Case Report Source Type: research

Intracerebral hemorrhage was the highest cause of mortality among stroke subtypes in Japanese dialysis patients
Source: Hemodialysis International - July 1, 2014 Category: Hematology Authors: Minako Wakasugi, Junichiro J. Kazama, Ichiei Narita Tags: Letter to the Editor Source Type: research

Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis in Critically Ill Patients
Abstract Management of volume status is difficult in critically ill patients with renal failure. Volumetric hemodynamic indices are increasingly being used to guide fluid therapy in the intensive care unit (ICU), but are not established to monitor hemodialysis‐induced fluid removal in critically ill patients. Using volumetric hemodynamic monitoring, changes in extravascular lung water index (EVLWI) and intrathoracic blood volume index (ITBVI) were measured immediately before and after hemodialysis sessions in 35 ICU patients. Additional hemodynamic and oxygenation related parameters were recorded at the same time, and on...
Source: Therapeutic Apheresis and Dialysis - September 4, 2014 Category: Hematology Authors: Friederike Compton, Marie Vogel, Walter Zidek, Markus Giet, Timm Westhoff Tags: Original Article Source Type: research

Clopidogrel Use in End‐Stage Kidney Disease
In conclusion, current evidence suggests that ESKD patients may not derive the same benefits from clopidogrel therapy as the general population and this therapy may be associated with harm. Properly designed observational studies and randomized controlled trials are needed to establish the role of clopidogrel in patients with ESKD, the use of platelet assays to tailor therapy, and the role of other antiplatelet agents such as prasugrel or ticagrelor in patients who exhibit high on‐treatment residual platelet reactivity.
Source: Seminars In Dialysis - November 1, 2014 Category: Hematology Authors: Bassem Y. Tanios, Houssam S. Itani, Deborah L. Zimmerman Tags: Review Source Type: research

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
In conclusion, based on these single-dose PK data, a supplementary dose of edoxaban may not be required following a haemodialysis session. Importantly, haemodialysis is not an effective mechanism for removal of edoxaban from the blood. PMID: 25566930 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 8, 2015 Category: Hematology Authors: Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS Tags: Thromb Haemost Source Type: research

Cold Hemodiafiltration for Exertional Heat Stroke Resulting in Multiple Organ Failure
Source: Therapeutic Apheresis and Dialysis - May 29, 2015 Category: Hematology Authors: Heng Fan, Jian‐hua Zhu, Ji‐hui Ye Tags: Letter to the Editor Source Type: research

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research

Antithrombotic therapy in end ‐stage renal disease
Abstract The delicate balance of risk vs. benefit of using antiplatelet and antithrombotic agents in the general population is well established. The decision to use these agents in the end stage renal disease (ESRD) population remains complex and difficult. The concomitant association of a prothombotic state with high risk of bleeding in the ESRD population requires individualization and careful clinical judgment before implementing such therapy. There remains a paucity of clinical trials and lack of substantial evidence in literature for safe and effective use of antithrombotic drugs in patients with advanced chronic kidn...
Source: Hemodialysis International - April 1, 2017 Category: Hematology Authors: Svetha Chunduri, Jon E. Folstad, Tushar J. Vachharajani Tags: Review Article Source Type: research

The physical deterioration of dialysis patients —Ignored, ill‐reported, and ill‐treated
Abstract The progressive physical deterioration of dialysis patients is apparent to all who are involved in their care. Exercise can help stem this decline, yet exercise uptake in chronic and end‐stage kidney disease is low. The involvement of exercise professionals has been shown to significantly increase patients’ physical function and improve their quality of life. However, exercise professionals are scarce in renal programs, far less than dietetic and social work services. A review of 10 years of renal exercise publications in the physical therapy and rehabilitation literature found that only 0.4% (7 out of a total...
Source: Seminars In Dialysis - June 5, 2017 Category: Hematology Authors: Paul N. Bennett, Nicole Capdarest ‐Arest, Kristen Parker Tags: EDITORIAL Source Type: research

A brief review of intradialytic hypotension with a focus on survival
Abstract Intradialytic hypotension (IDH), a common complication of ultrafiltration during hemodialysis therapy, is associated with high mortality and morbidity. IDH, defined as a nadir systolic blood pressure of less than 90 mm Hg on more than 30% of treatments, is a relevant definition and is correlated with mortality. Risk factors for IDH include patient demographics, anti‐hypertensive medication use, larger interdialytic weight gain, and dialysis prescription features as dialysate sodium, high ultrafiltration rate, and dialysate temperature. A high frequency of IDH events carries a substantial death risk. An ultrafilt...
Source: Seminars In Dialysis - May 1, 2017 Category: Hematology Authors: Jason A. Chou, Kamyar Kalantar ‐Zadeh, Anna T. Mathew Tags: INTRADIALYTIC HYPOTENSION: PERSPECTIVES IN CONTEMPORARY PRACTICE Source Type: research

Pages: 1 2 3